Robert F. Kennedy Jr.

Well, FDA does an $88 billion under him for Pfizer, and then he goes back to work for Pfizer again. So Alex Azar is another lobbyist from the – pharmaceutical industry who gets appointed to the head of NIH. And you look at all of the regulatory agencies, they were all being run by people who were within those industries. And I'm not going to do that.

I'm going to bring people of integrity into government and, you know, who will change the culture of those agencies and reward the branch and division chairs that actually are doing public health. And I'm going to get rid of I'm going to change some of the policies about the report that allows these, you know, I think the last...

I'm going to bring people of integrity into government and, you know, who will change the culture of those agencies and reward the branch and division chairs that actually are doing public health. And I'm going to get rid of I'm going to change some of the policies about the report that allows these, you know, I think the last...

I'm going to bring people of integrity into government and, you know, who will change the culture of those agencies and reward the branch and division chairs that actually are doing public health. And I'm going to get rid of I'm going to change some of the policies about the report that allows these, you know, I think the last...

Six FDA chiefs have gone to work for pharmaceutical companies within a year of leaving the FDA.

Six FDA chiefs have gone to work for pharmaceutical companies within a year of leaving the FDA.

Six FDA chiefs have gone to work for pharmaceutical companies within a year of leaving the FDA.

Another thing that we can do is You know, and I'm saying this with a due concern for privacy or individual privacy, but you can depersonalize medical records and digitalize. A lot of them are digitalized anyway. Once they're digitalized, you can do a medical informatic system that essentially is constantly doing epidemiological studies on every drug.

Another thing that we can do is You know, and I'm saying this with a due concern for privacy or individual privacy, but you can depersonalize medical records and digitalize. A lot of them are digitalized anyway. Once they're digitalized, you can do a medical informatic system that essentially is constantly doing epidemiological studies on every drug.

Another thing that we can do is You know, and I'm saying this with a due concern for privacy or individual privacy, but you can depersonalize medical records and digitalize. A lot of them are digitalized anyway. Once they're digitalized, you can do a medical informatic system that essentially is constantly doing epidemiological studies on every drug.

and comparing one diabetes drug outcome to another diabetes drug outcome, and then saying, we're only gonna pay for the one where we maximize the bang for buck. And none of that happens. There's none of those kind of everything, Everybody is at the mercy of the pharmaceutical reps. You know, the doctors are prescribing what they tell them to prescribe.

and comparing one diabetes drug outcome to another diabetes drug outcome, and then saying, we're only gonna pay for the one where we maximize the bang for buck. And none of that happens. There's none of those kind of everything, Everybody is at the mercy of the pharmaceutical reps. You know, the doctors are prescribing what they tell them to prescribe.

and comparing one diabetes drug outcome to another diabetes drug outcome, and then saying, we're only gonna pay for the one where we maximize the bang for buck. And none of that happens. There's none of those kind of everything, Everybody is at the mercy of the pharmaceutical reps. You know, the doctors are prescribing what they tell them to prescribe.

And, you know, the public is at the mercy of an FDA that is owned. You know, the FDA is just a stock puppet. And the industry is supposed to regulate. And, you know, all of this is easily changed. I'm not saying it's, you know, I'm going to be able to accomplish it all on day one, but I'm going to accomplish it very quickly.

And, you know, the public is at the mercy of an FDA that is owned. You know, the FDA is just a stock puppet. And the industry is supposed to regulate. And, you know, all of this is easily changed. I'm not saying it's, you know, I'm going to be able to accomplish it all on day one, but I'm going to accomplish it very quickly.

And, you know, the public is at the mercy of an FDA that is owned. You know, the FDA is just a stock puppet. And the industry is supposed to regulate. And, you know, all of this is easily changed. I'm not saying it's, you know, I'm going to be able to accomplish it all on day one, but I'm going to accomplish it very quickly.

And, you know, what I've said to people, if I haven't dramatically reduced the occurrence of chronic disease in children by my third year in office, that people shouldn't vote for me again. You know, I'm that confident that I'm going to be able to change this.

And, you know, what I've said to people, if I haven't dramatically reduced the occurrence of chronic disease in children by my third year in office, that people shouldn't vote for me again. You know, I'm that confident that I'm going to be able to change this.

And, you know, what I've said to people, if I haven't dramatically reduced the occurrence of chronic disease in children by my third year in office, that people shouldn't vote for me again. You know, I'm that confident that I'm going to be able to change this.

Yeah. And, you know, that debate between, you know, Medicaid for all or, you know, whether there's a public private, you know, a public option or. a gradual integration or, you know, whatever it is, Obamacare, it's all about moving deck chairs around in the Titanic. Because, you know, the thing that's driving costs, it's shifting costs from one person to another.